Aram Chang currently serves as a Principal Scientist at Bristol Myers Squibb, where he leverages over 15 years of extensive experience in protein biochemistry and structural biology to drive innovative research and development initiatives. In his role, Aram leads the recombinant protein purification group, overseeing...
Aram Chang currently serves as a Principal Scientist at Bristol Myers Squibb, where he leverages over 15 years of extensive experience in protein biochemistry and structural biology to drive innovative research and development initiatives. In his role, Aram leads the recombinant protein purification group, overseeing the production of high-quality protein samples at scale, ranging from 100 mL to 10 L. This critical work supports a variety of applications, including in vivo and in vitro experiments, biophysical characterization, and developability assessments for therapeutic candidates.
Aram's expertise encompasses a wide array of techniques fundamental to the pharmaceutical industry, including X-ray crystallography, small angle X-ray scattering, and advanced molecular cloning strategies. His command of protein expression systems—both bacterial and eukaryotic—enables him to design and optimize constructs for the efficient production of monoclonal, bispecific, and engineered antibodies, as well as Fabs and antigens. This multifaceted skill set not only enhances the quality of protein characterization and sample quality control but also ensures the timely distribution of critical samples across various research teams.
Throughout his tenure at Bristol Myers Squibb, Aram has been instrumental in key projects that bridge the gap between basic research and clinical application, contributing to the development of next-generation therapeutics. His collaborative approach and commitment to scientific excellence position him as a vital asset in advancing the company’s mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
